Presenter's Information

Name Ron Waksman
Country United States
Job Interventional Cardiologist

Other content(s) by This Presenter


  1. Intervention of DES ISR Using High-Pressure Inflation of Non-Compliant Balloon
  2. LM Bifurcation Disease
  3. BMS and Radiotherapy Failure
  4. Tight ISR of Proximal LCX Lesion Treated with Drug Eluting Balloon and Distal Edge ISR of Proximal LAD Stent with Drug Eluting Stent
  5. LAD Bifurcation Lesion Treated by Single Stent Placement

Slide Presentations

  1. Metallic Biodegradeable Stent
  2. Final Results From the ORBIT Clinical Trials
  3. REWARDS: Non- Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents in the Real World: 1-Year Results From a Large, Single Center Registry
  4. Regional Photodynamic Therapy for Vulnerable Plaque Stabilization
  5. i2 Late-Breaking New Technologies Highlights
  6. DES Thrombosis How Long Patients Will Be on Dual Antiplatelet Therapy?
  7. Bioabsorbable Stent Technology
  8. Treatment Modalities for Diagnosing and Treatment of Vulnerable Plaque
  9. Nuts and Bolts of Clinical Trials: DSMB, Event Committees, Core Labs, Data Standards
  10. How Long Patients Will Be on Dual Antiplatelet Therapy?
  11. The Clinical Spectrum of DES Thrombosis: Multifactorial Causes, Clinical Presentations, and Recommended Treatment Strategies
  12. Not So Fast: The Data Are Circumstantial
  13. Perspectives on the Use of Fondaparinux in ACS: Transitioning to the Cath Lab
  14. Not Stenting, Conservative Medical Therapy Is the Best Choice.
  15. Emerging Technologies
  16. Future in Vulnerable Plaque Imaging
  17. Structural Heart Disease Intervention: \"New Opportunities to the Interventional Cardiologist with Structural Heart Disease\"
  18. Strategies for PCI of SVG Disease
  19. Treatment of DES In-Stent Restenosis
  20. Nanoparticle or Nanomatrix Technologies for DES
  21. Aortic Valvuloplasty in 2009: Indications and Results
  22. The BIOTRONIK Bioabsorbable Magnesium Scaffold DREAMS
  23. Role of Genotyping and Point-of-Care Testing in Clopidogrel, Parsugrel, and Ticagrelor
  24. Not a Believer: All Plaques Are Potentially Vulnerable!
  25. Can IVUS Predict FFR? Lessons from VERDICT and F1RST
  26. Featured Lecture: The Gold Standard for PCI Will Be Bioabsorbable DES in 5-10 Years
  27. Against: Dispelling Myths, No Benefits in Reality
  28. Update on the Drug-eluting Magnesium Absorbable Scaffold: Two-year Results from the BIOSOLVE Trial
  29. Highlights of Recent Clinical Trials from ACCi2.13: Cangrelor for PCI, Statins for CIN and PE Treatment
  30. No Benefits, Time to Rethink?
  31. [Early vs. New Devices] Pro: SYMPLICITY Obviate Imprudent New Devices
  32. Focusing on the Clinical Importance of Conformability
  33. What Can We Look Forward to from the Magnesium Scaffold?
CardioVascular Research Foundation (CVRF)
2nd Floor, Asan Institute for Education & Research, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea
Tel_82.2.3010.4792 | Fax_82.2.475.6898
재단법인 심장혈관연구재단
대표이사 박승정 | 서울시 송파구 올림픽로43길 88, 서울아산병원 아산교육연구관 2층 | 사업자등록번호 215-82-06387
개인정보 관리책임자_노순정 | 전화번호_02.3010.4792 | 팩스번호_02.475.6898
Copyright © CVRF, Seoul, Korea. All rights reserved.